Last $4.03 USD
Change Today +0.06 / 1.51%
Volume 192.7K
NEO On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

neogenomics inc (NEO) Snapshot

Open
$3.98
Previous Close
$3.97
Day High
$4.09
Day Low
$3.89
52 Week High
09/10/14 - $6.10
52 Week Low
04/15/14 - $2.95
Market Cap
241.7M
Average Volume 10 Days
425.0K
EPS TTM
$0.03
Shares Outstanding
60.0M
EX-Date
--
P/E TM
129.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for NEOGENOMICS INC (NEO)

Related News

No related news articles were found.

neogenomics inc (NEO) Related Businessweek News

No Related Businessweek News Found

neogenomics inc (NEO) Details

NeoGenomics, Inc., together with its subsidiary, NeoGenomics Laboratories, Inc., operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company performs analyses for hematopoietic cancers, such as leukemia and lymphoma; and solid tumor cancers comprising breast, lung, colon, and bladder cancer. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry testing services to identify cell proteins in a tissue section; and molecular testing services that focus on the analysis of DNA and RNA, as well as on the structure and function of genes at the molecular level. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

315 Employees
Last Reported Date: 05/8/14
Founded in 2001

neogenomics inc (NEO) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $557.0K
Chief Financial Officer
Total Annual Compensation: $305.5K
Chief Medical Officer and Director of Researc...
Total Annual Compensation: $92.5K
Chief Compliance Officer, Executive Vice Pres...
Total Annual Compensation: $72.5K
Compensation as of Fiscal Year 2013.

neogenomics inc (NEO) Key Developments

NeoGenomics, Inc. Revises Consolidated Earnings Guidance for the Fourth Quarter of Fiscal 2014

NeoGenomics Inc. revised consolidated earnings guidance for the fourth quarter of fiscal 2014. The company announced that it was raising its previously issued revenue and earnings per share guidance for the fourth quarter of 2014. The company now expects revenue of approximately $25 million and earnings per share of approximately $0.01 - $0.02 for the fourth quarter. Previously, the company had issued revenue guidance of $23.0 million to $24.5 million and earnings per share guidance of $0.00 to $0.01 per share. On a consolidated basis, including the results of the company’s newly acquired PathLogic business, it is expecting approximately 36% year over year revenue growth in the fourth quarter. Approximately 23% of this growth is coming from the company’s core NeoGenomics business and the remainder from PathLogic.

NeoGenomics, Robert H. Lurie Comprehensive Cancer Center of Northwestern University and NMDTI Enter into Research Agreement

NeoGenomics Inc. has entered into a research agreement with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, or Lurie Cancer Center, and the Northwestern Medicine Developmental Therapeutics Institute, or NMDTI, to initiate a translational program designed to expand the established clinical utility of comprehensive genomic profiling technologies in the development of oncology therapeutics. The Lurie Cancer Center and NMDTI expect to conduct a broad range of research studies with NeoGenomics that will expand current protocols focused on matching cognate agents with targets identified by the NeoTYPE line of cancer profiling tests.

Neogenomics Inc. Appoints Crowe Horwath LLP as Independent Registered Public Accounting Firm for the Fiscal Year of 2014

The Audit Committee of the Board of Directors of Neogenomics Inc. has completed a competitive process to review the appointment of the company's independent registered public accounting firm for the 2014 fiscal year. As a result of this process, effective November 12, 2014, the company engaged Crowe Horwath LLP as the company's independent registered public accounting firm.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEO:US $4.03 USD +0.06

NEO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzo Biochem Inc $3.15 USD +0.02
Foundation Medicine Inc $47.66 USD -0.45
Psychemedics Corp $14.96 USD -0.03
Response Genetics Inc $0.43 USD +0.0107
Rosetta Genomics Ltd $3.02 USD -0.11
View Industry Companies
 

Industry Analysis

NEO

Industry Average

Valuation NEO Industry Range
Price/Earnings 100.0x
Price/Sales 2.7x
Price/Book 4.1x
Price/Cash Flow 256.6x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOGENOMICS INC, please visit www.neogenomics.org. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.